Lecanemab in Real-World Practice: What Early Alzheimer’s Patients Are Actually Experiencing Review Abstract Lecanemab represents a major milestone in the treatment of Alzheimer’s disease as the first anti amyloid monoclonal antibody to receive traditional approval from the United States Food and Drug Administration for patients with early
Tag: disease modifying therapy
MS Phenotypes: Why the Current Classification System May Be Failing Patients
MS Phenotypes: Why the Current Classification System May Be Failing Patients Review Key Takeaways The traditional classification system for multiple sclerosis, established in 1996 by the United States National Multiple Sclerosis Society, continues to shape clinical practice, therapeutic decision making, and clinical trial design nearly three
